GlassScriptPhysician profile
Lynn C Smitherman
NPI 1609814722
$25,346.02
in general payments reported to CMS, 2019-2025
13 companies · $90.84 in 2025
The $90.84 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $963 · 2021: $1,735 · 2022: $18K · 2023: $4,007 · 2024: $78.71 · 2025: $90.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,836 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,775 · Food and Beverage: $559 · Travel and Lodging: $6.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,836.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,774.50 |
| Food and Beverage | $559.36 |
| Travel and Lodging | $6.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $24,732.39 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $148.92 | 2019-2023 | Austedo Xr |
| Boston Scientific Corporation | $130.85 | 2023 | Watchman Access System |
| Amgen INC. | $81.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $48.88 | 2023 | |
| Merck Sharp & Dohme LLC | $41.24 | 2022-2025 | Gardasil 9, Recombivax Hb, Vaxelis |
| Astrazeneca Pharmaceuticals LP | $38.69 | 2022-2024 | Flumist Quadrivalent |
| Pfizer INC. | $25.43 | 2021 | |
| Alexion Pharmaceuticals, INC. | $24.99 | 2022 | |
| Alk-Abello, INC | $23.22 | 2025 | Neffy |
| Azurity Pharmaceuticals, INC. | $18.86 | 2024 | Triptodur |
| Sequel Med Tech, LLC | $18.80 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Smitherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.